RU2019125343A - Новое применение мутантного фактора роста фибробластов человека пролонгированного действия - Google Patents
Новое применение мутантного фактора роста фибробластов человека пролонгированного действия Download PDFInfo
- Publication number
- RU2019125343A RU2019125343A RU2019125343A RU2019125343A RU2019125343A RU 2019125343 A RU2019125343 A RU 2019125343A RU 2019125343 A RU2019125343 A RU 2019125343A RU 2019125343 A RU2019125343 A RU 2019125343A RU 2019125343 A RU2019125343 A RU 2019125343A
- Authority
- RU
- Russia
- Prior art keywords
- nash
- induced
- use according
- injections
- fibroblast growth
- Prior art date
Links
- 230000002035 prolonged effect Effects 0.000 title claims 2
- 210000002950 fibroblast Anatomy 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 12
- 239000007924 injection Substances 0.000 claims 7
- 238000002347 injection Methods 0.000 claims 7
- 230000003247 decreasing effect Effects 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 1
- 108010082126 Alanine transaminase Proteins 0.000 claims 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 101001051974 Mus musculus Fibroblast growth factor 21 Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000026589 Wolman disease Diseases 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Применение мутантного фактора роста фибробластов человека пролонгированного действия в получении лекарственных средств для лечения неалкогольного стеатогепатита.
2. Применение по п. 1, где мутантный фактор роста фибробластов человека пролонгированного действия представляет собой пегилированный рекомбинантный химерный фактор роста фибробластов-21 человека-мыши (FG) или его фармацевтически приемлемую соль.
3. Применение по п. 2, где применение выбрано из снижения уровней аланинаминотрансферазы и аспартатаминотрансферазы в сыворотке крови, уменьшения стеатоза и лобулярного воспаления, снижения степени гепатоцеллюлярной баллонирующей дистрофии и уменьшения поражения печени.
4. Применение по п. 1, где неалкогольный стеатогепатит (NASH) выбран из индуцированного гепатитом NASH, индуцированного ожирением NASH, индуцированного диабетом NASH, индуцированного инсулинорезистентностью NASH, индуцированного гипертриглицеридемией NASH, индуцированного абеталипопротеинемией NASH, NASH, индуцированного болезнью накопления гликогена, NASH, индуцированного болезнью Уэйка, NASH, индуцированного болезнью Вольмана, или индуцированного липодистрофией NASH.
5. Применение по п. 2, где лекарственные средства представляют собой фармацевтические композиции, содержащие FG или его фармацевтически приемлемую соль в качестве активного фармацевтического ингредиента.
6. Применение по п. 5, где фармацевтические композиции могут быть получены в виде любой фармацевтически приемлемой лекарственной формы.
7. Применение по п. 6, где лекарственные формы выбраны из таблеток, капсул, гранул, пилюль, порошков, мази, препарата, полученного с помощью сублимационной сушки, пылеобразных порошков, растворов, инъекционных препаратов, суппозиториев, распыляемых растворов, каплей, пластырей и драже.
8. Применение по п. 7, где лекарственные формы выбраны из порошков для приготовления инъекционного препарата или жидких инъекционных препаратов.
9. Применение по п. 8, где жидкие инъекционные препараты выбраны из водных инъекционных препаратов, инъекционных препаратов, содержащих органический растворитель, и суспензионных инъекционных препаратов.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710172824.0A CN108619490A (zh) | 2017-03-22 | 2017-03-22 | 一种长效化突变的人源成纤维生长因子的新用途 |
| CN201710172824.0 | 2017-03-22 | ||
| PCT/CN2018/079482 WO2018171557A1 (zh) | 2017-03-22 | 2018-03-19 | 一种长效化突变的人源成纤维生长因子的新用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019125343A true RU2019125343A (ru) | 2021-02-09 |
| RU2019125343A3 RU2019125343A3 (ru) | 2021-03-31 |
| RU2785582C2 RU2785582C2 (ru) | 2022-12-08 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| JP7491839B2 (ja) | 2024-05-28 |
| US20250042964A1 (en) | 2025-02-06 |
| JP2020511545A (ja) | 2020-04-16 |
| CN110520146A (zh) | 2019-11-29 |
| WO2018171557A1 (zh) | 2018-09-27 |
| CA3049703A1 (en) | 2018-09-27 |
| CN108619490A (zh) | 2018-10-09 |
| EP3603660A4 (en) | 2021-01-13 |
| US20190367574A1 (en) | 2019-12-05 |
| RU2019125343A3 (ru) | 2021-03-31 |
| EP3603660A1 (en) | 2020-02-05 |
| US12152059B2 (en) | 2024-11-26 |
| EP3603660B1 (en) | 2025-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110520146A (zh) | 一种长效化突变的人源成纤维生长因子的新用途 | |
| HRP20251088T1 (hr) | Upotreba dugodjelujućih peptida glp‑1 | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| JP2015517488A5 (ru) | ||
| HRP20170358T1 (hr) | Inhibitori histonskih demetilaza | |
| WO2014012069A3 (en) | Dry powder drug delivery systems and methods | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| NZ703153A (en) | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof | |
| MX383971B (es) | Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. | |
| HRP20191923T1 (hr) | Postupci i sastavi za isporuku arilsulfataze a u cns | |
| WO2009033770A3 (en) | Calcitonin c-terminal flanking peptide for use as a therapeutic agent | |
| JP2016512564A5 (ru) | ||
| NZ600477A (en) | Insulin analogues with chlorinated amino acids | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| WO2016109823A8 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| WO2018226058A3 (ko) | 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 | |
| EA201591768A1 (ru) | Дозированные препараты в качестве модуляторов опиоидного рецептора | |
| RU2016118398A (ru) | Слитый белок на основе рекомбинантного иммунорегуляторного белка ганодермы и сывороточного альбумина человека, способ его получения, а также его применение | |
| CN105461781A (zh) | 一种茶皂苷元锌配合物及其制备方法和用途 | |
| JP2009506978A5 (ru) | ||
| HRP20241042T1 (hr) | Novi analozi inzulina i njihova upotreba | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| JP2014504601A5 (ru) | ||
| RU2013103051A (ru) | Способ терапии бронхо-констриктивных состояний | |
| JP2019506840A5 (ru) |